Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does UPADACITINIB Cause Wrong technique in product usage process? 47 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 47 reports of Wrong technique in product usage process have been filed in association with UPADACITINIB (Rinvoq). This represents 0.1% of all adverse event reports for UPADACITINIB.

47
Reports of Wrong technique in product usage process with UPADACITINIB
0.1%
of all UPADACITINIB reports
2
Deaths
4
Hospitalizations

How Dangerous Is Wrong technique in product usage process From UPADACITINIB?

Of the 47 reports, 2 (4.3%) resulted in death, 4 (8.5%) required hospitalization.

Is Wrong technique in product usage process Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for UPADACITINIB. However, 47 reports have been filed with the FAERS database.

What Other Side Effects Does UPADACITINIB Cause?

Pain (4,444) Arthralgia (3,815) Drug ineffective (3,384) Covid-19 (2,978) Rheumatoid arthritis (2,730) Pain in extremity (2,353) Fatigue (2,153) Fall (2,081) Surgery (2,037) Therapy interrupted (1,741)

What Other Drugs Cause Wrong technique in product usage process?

EVOLOCUMAB (21,664) ALBUTEROL (17,114) ADALIMUMAB (11,766) PEGFILGRASTIM (10,217) ETANERCEPT (9,835) ERENUMAB-AOOE (9,359) SACUBITRIL\VALSARTAN (8,022) LEUPROLIDE (5,062) FENTANYL (2,812) SEMAGLUTIDE (2,538)

Which UPADACITINIB Alternatives Have Lower Wrong technique in product usage process Risk?

UPADACITINIB vs URAPIDIL UPADACITINIB vs UREA UPADACITINIB vs URIDINE TRIACETATE UPADACITINIB vs UROFOLLITROPIN UPADACITINIB vs URSODIOL

Related Pages

UPADACITINIB Full Profile All Wrong technique in product usage process Reports All Drugs Causing Wrong technique in product usage process UPADACITINIB Demographics